AGATE, LAURA
 Distribuzione geografica
Continente #
NA - Nord America 5.224
EU - Europa 5.058
AS - Asia 1.018
AF - Africa 256
SA - Sud America 23
OC - Oceania 6
Continente sconosciuto - Info sul continente non disponibili 2
Totale 11.587
Nazione #
US - Stati Uniti d'America 5.103
DE - Germania 2.006
IT - Italia 974
SE - Svezia 817
CN - Cina 441
GB - Regno Unito 421
BG - Bulgaria 270
SG - Singapore 233
AT - Austria 219
CI - Costa d'Avorio 146
CA - Canada 117
SN - Senegal 104
RU - Federazione Russa 103
VN - Vietnam 99
TR - Turchia 82
UA - Ucraina 73
FI - Finlandia 57
IN - India 57
HK - Hong Kong 43
CH - Svizzera 31
BE - Belgio 18
FR - Francia 13
NL - Olanda 12
JP - Giappone 11
IR - Iran 10
PL - Polonia 10
IL - Israele 7
AU - Australia 6
CL - Cile 6
KR - Corea 6
PH - Filippine 6
TW - Taiwan 6
GR - Grecia 5
ID - Indonesia 5
IE - Irlanda 5
BR - Brasile 4
CZ - Repubblica Ceca 4
RO - Romania 4
AR - Argentina 3
AZ - Azerbaigian 3
EC - Ecuador 3
RS - Serbia 3
SK - Slovacchia (Repubblica Slovacca) 3
VE - Venezuela 3
BY - Bielorussia 2
EG - Egitto 2
HU - Ungheria 2
MX - Messico 2
MY - Malesia 2
SV - El Salvador 2
TH - Thailandia 2
UY - Uruguay 2
A1 - Anonimo 1
CO - Colombia 1
DK - Danimarca 1
DZ - Algeria 1
ES - Italia 1
EU - Europa 1
GE - Georgia 1
HR - Croazia 1
IS - Islanda 1
KZ - Kazakistan 1
LA - Repubblica Popolare Democratica del Laos 1
MA - Marocco 1
MN - Mongolia 1
NG - Nigeria 1
NO - Norvegia 1
PE - Perù 1
PT - Portogallo 1
SA - Arabia Saudita 1
ZA - Sudafrica 1
Totale 11.587
Città #
Woodbridge 658
Chandler 580
Fairfield 490
Ann Arbor 403
Ashburn 386
Milan 357
Houston 304
Sofia 270
Seattle 214
Wilmington 208
Vienna 203
New York 195
Cambridge 181
Beijing 178
Abidjan 146
Princeton 138
Lawrence 106
Dakar 104
Ottawa 102
Jacksonville 91
Florence 85
Serra 85
London 84
Medford 80
Singapore 72
Frankfurt am Main 58
Izmir 56
Nanjing 56
Bremen 52
Dearborn 52
Des Moines 51
Boulder 50
Dong Ket 49
Pisa 44
San Diego 37
Rome 36
Redmond 34
Hong Kong 31
Lancaster 28
Bern 27
Redwood City 25
Los Angeles 24
Ogden 24
Nanchang 20
Washington 20
Brussels 17
Jiaxing 16
Kunming 14
Jüchen 13
Changsha 12
Munich 12
Ningbo 11
Norwalk 11
Chiesina Uzzanese 10
Düsseldorf 10
Guangzhou 10
Nürnberg 10
Vicopisano 10
Hefei 9
Kocaeli 9
Pune 9
Shenyang 9
Tianjin 9
Zhengzhou 9
Hebei 8
Phoenix 8
Scandicci 8
Toronto 8
Chengdu 7
Hangzhou 7
Istanbul 7
Jinan 7
Boardman 6
Falls Church 6
Grafing 6
Shanghai 6
Wuhan 6
Chicago 5
Dallas 5
Pontedera 5
Salt Lake City 5
Samsun 5
San Francisco 5
Urmia 5
Edinburgh 4
Fuzhou 4
Marseille 4
Montreal 4
Parma 4
Santiago 4
Amsterdam 3
Atakum 3
Bengaluru 3
Bratislava 3
Brno 3
Civitanova Marche 3
Detroit 3
Dublin 3
Genoa 3
Hatfield 3
Totale 6.883
Nome #
ALL-TRANS RETINOIC ACID TREATMENT INHIBITS THE GROWTH OF RARb mRNA EXPRESSING THYROID CANCER CELL LINES BUT DOES NOT RE-INDUCE THE EXPRESSION OF THYROID SPECIFIC GENES 192
Celecoxib, a cyclooxygenase-2 inhibitor, potentiates the chemotherapic effect of vinorelbine in the medullary thyroid cancer TT cell line. 191
Are the clinical and pathological features of differentiated thyroid carcinoma really changed over the last 35 years? Study on 4187 patients from a single Italian institution to answer this question. 186
Polymorphisms within base and nucleotide excision repair pathways and risk of differentiated thyroid carcinoma 184
The presence of a tall cells>10% in a classical variant of papillary thyroid carcinoma (CV-PTC) makes its aggressiveness similar to that of tall cell variant (TCV-PTC) 178
Ciglitazone induces cell growth inhibition in a medullary thyroid carcinoma cell line (TT) likely by an increase of PPARgamma expression 174
Outcome of differentiated thyroid cancer with detectable serum Tg and negative diagnostic (131)I whole body scan: comparison of patients treated with high (131)I activities versus untreated patients 170
In silico and in vitro analysis of rare germline allelic variants of RET oncogene associated with medullary thyroid cancer 170
Identification of a novel point mutation in the RET gene (Ala883Thr), which is associated with medullary thyroid carcinoma phenotype only in homozygous condition 161
Celecoxib, a cyclooxygenase-2 inhibitor, potentiates the chemotherapic effect of vinorelbine in the medullary thyroid cancer TT cell line 160
Anaplastic thyroid carcinoma: from clinicopathology to genetics and advanced therapies 158
Prophylactic central compartment lymph node dissection in papillary thyroid carcinoma: Clinical implications derived from the first prospective randomized controlled single institution study 151
Targeted Therapy in Thyroid Cancer: State of the Art 151
All-trans Retinoic Acid treatment inhibits the growth of RARb mRNA expressing thyroid cancer cell lines but does not re-induce the expression of thyroid specific genes 147
CLINICAL IMPACT OF RET GENETIC SCREENING IN THE MANAGEMENT OF MEDULLARY THYROID CARCINOMA (MTC) PATIENTS: 20 YEARS OF EXPERIENCE 147
null 146
Changing Trend of Thyroglobulin Antibodies in Patients with Differentiated Thyroid Cancer Treated with Total Thyroidectomy Without ¹³¹I Ablation 146
Medullary thyroid cancer treated with vandetanib: predictors of longer and durable response 145
A complex MEN2 syndrome, a mixture of 2B and 2A, associated with a new RET germiline deletion. 143
Treatment of advanced thyroid cancer with targeted therapies: Ten years of experience 142
RET/PTC rearrangements in Belarus, Ukrainian and Russian pos Chernobyl thyroid tumors 138
Ablation of thyroid residues with 30 mCi (131)I: a comparison in thyroid cancer patients prepared with recombinant human TSH or thyroid hormone withdrawal 138
Prevalence of papillary thyroid cancer (PTC) in patients affected by medullary thyroid cancer (MTC) 135
RET point mutations in Thyroid Carcinoma 133
Thyroglobulin Antibodies (TgAb) Titer Spontaneously Decrease Until The Negativization Or Stabilization In Most Of Cases Of Papillary Thyroid Microcarcinoma (mPTC) Treated With Total Thyroidectomy But Not Ablated With 131I 133
Hypertension, nausea, anorexia and weight loss were significantly associated with better progression-free survival in patients with radioiodine-Refractory Differentiated Thyroid Carcinoma treated with Lenvatinib 133
RET genetic screening of sporadic medullary thyroid cancer (MTC) allows the preclinical diagnosis of unsuspected gene carriers and the identification of a relevant percentage of hidden familial MTC (FMTC) 133
Re-differentiation of thyroid carcinoma cell lines treated with 5-Aza-2'-deoxycytidine and retinoic acid 127
Nuove indicazioni all’impiego del TSH umano ricombinante (rhTSH) e basse attività di 131I nella radioablazione del residuo tiroideo post-chirurgico. 124
Contralateral papillary thyroid cancer is frequent at completion thyroidectomy with no difference in low- and high-risk patients 123
null 122
Lenvatinib therapy in progressive, radioiodine-refractory, differentiated thyroid carcinoma: analysis of 74 cases followed in a single centre 122
Lung recurrence of papillary thyroid cancer diagnosed with antithyroglobulin antibodies after 10 years from initial treatment. 121
New and old knowledge on differentiated thyroid cancer epidemiology and risk factors. 120
Ret Genetic Screening in Patients with Medullary Thyroid Cancer and Their Relatives: Experience with 807 Individuals at One Center 120
Il carcinoma tiroideo: nuove prospettive terapeutiche. 120
Thyroid consequences of the Chernobyl nuclear accident. 118
Successo terapeutico di Lenvatinib in seconda linea in un caso di carcinoma follicolare della tiroide avanzato 117
, Descrizione della prima mutazione omozigote germinale di RET (Ala883->Thr) che non determina l'insorgenza del carcinoma midollare della tiroide in condizioni di eterozigosi 116
Retinoic acid receptor beta2 re-expression and growth inhibition in thyroid carcinoma cell lines after 5-aza-2'-deoxycytidine treatment 116
Thyroid autoantibodies and thyroid function in subjects exposed to Chernobyl fallout during childhood: evidence for a transient radiation-induced elevation of serum thyroid antibodies without an increase in thyroid autoimmune disease. 116
Recombinant human TSH (rhTSH) in 2009: new perspectives in diagnosis and therapy 115
Twenty years of lesson learning: How does the RET genetic screening test impact the clinical management of medullary thyroid cancer? 115
Correlation between early and 24th hour 131-I uptake in post-surgical thyroid remnant evaluation 114
null 114
The stage of differentiated thyroid cancer at diagnosis is significantly more advanced in children than in adolescent 112
Role of Thyroglobulin, Neck Ultrasound, Thyroglobulin Antibodies Trend and Diagnostic Whole Body Scan in the Management of Differentiated Thyroid Cancer Patients with Persistent Thyroglobulin Antibodies 112
ROLE OF THYROID REMNANT ABLATION WITH LOW ACTIVITY OF 131I IN PATIENTS WITH LOW AND INTERMEDIATE RISK PAPILLARY THYROID CARCINOMA (PTC). 111
Active surveillance in papillary thyroid microcarcinomas is feasible and safe: experience at one single Italian center 111
Delayed 131-I First Treatment After Surgery has No Impact on the Median Term Outcome of Patients with Intermediate Risk Differentiated Thyroid Cancer 111
Failure to use measurement of megalin secretory components complexed with serum thyroglobulin as a tool to identify metastases after surgery in papillary thyroid cancer. 110
Fifty years after the first description, the MEN 2B syndrome diagnosisis still late: description of two recent cases 110
In vitro studies of retnoic acid treatment of human anaplastic, poorly differentiated papillary, follicular and medullary thyroid cancer cell lines 109
Recombinant human thyrotropin-stimulated serum thyroglobulin combined with neck ultrasonography has the highest sensitivity in monitoring differentiated thyroid carcinoma 109
Thyroid incidentaloma 108
Prediction of disease status by recombinant human TSH-stimulated serum Tg in the postsurgical follow-up of differentiated thyroid carcinoma 108
null 107
Active Surveillance In Papillary Thyroid Microcarcinomas (PMCS): A 2 Years Follow Up (FU) At A Single Center 107
null 105
null 103
Advantages and disadvantages of prophylactic central compartment lymph node dissection for differentiated thyroid cancer: the first randomized controlled study from a single referral center. 101
5 YEARS FOLLOW UP OF THYROGLOBULIN (TG), THYROGLOBULIN ANTIBODIES (TGAB) AND NECK ULTRASOUND (US) IN PATIENTS WITH PAPILLARY THYROID MICROCARCINOMA (MPTC) TREATED WITH TOTAL THYROIDECTOMY BUT NOT ABLATED WITH 131I 101
Low specificity of blood thyroglobulin messenger ribonucleic acid assay prevents its use in the follow up of differentiated thyroid cancer patients 100
BRAFV600E mutation is an indipendent predictive prognostic factor for persistent/recurrent disease in low risk differentiated Thyroid cancer patients: a 5 year follow-up study. 100
A rare adverse event (AE) in a group of radioiodine-refractory differentiated thyroid cancer (RAI-R DTC) patients in therapy with lenvatinib. 99
Treatment of advanced thyroid cancer with axitinib: Phase 2 study with pharmacokinetic/pharmacodynamic and quality-of-life assessments 96
Less than 2% of the low- and intermediate-risk differentiated thyroid cancers show distant metastases at post-ablation whole-body scan 96
Lenvatinib treatment in the real clinical practice of progressive, radioiodine-refractory differentiated thyroid carcinoma: analysis of a big series followed in a single center 92
Studi in vitro del trattamento con acido retinico di linee di carcinoma tiroideo umano anaplastico, poco differenziato, follicolare e midollare 91
5 Years Follow Up Of Thyroglobulin (Tg), Thyroglobulin Antibodies (Tgab) And Neck Ultrasound (Nus) In Patients With Papillary Thyroid Microcarcinoma (Mptc) Treated With Total Thyroidectomy But Not Ablated With 131I 91
Delayed radioiodine remnant ablation (RRA) does not impact on the outcome of intermediate risk for recurrence differentiated thyroid cancer patients (IR-DTC). 90
Outcome of classical (CVPTC) and follicular (FVPTC) variants of papillary thyroid cancer: 15 years of follow-up 87
null 86
null 84
Thyroglobulin changes are highly dependent on TSH in low-risk DTC patients not treated with 131I 84
Recombinant Human Thyrotropin Stimulation Thyroglobulin (rhTSH-Tg) test can identify false serum tg due to heterophilic antibodies in differentiated thyroid cancer (DTC) patients 83
Correlation Between The Presence Of Macrophages And Braf V600e Mutation In Different Variants Of Well Differentiated Papillary Thyroid Cancer 83
Radioiodine remnant ablation (RRA) Impact on the dynamic risk of restratification in the short-term follow-up of patients with differentiated thyroid cancer (DTC). 82
The Thymic Hyperplasia (TH) And Biochemical Persistence Of Disease In Patients With Differentiated Thyroid Carcinoma (DTC) 82
Low-Risk Differentiated Thyroid Cancer with BRAFV600E mutation is more difficult to cure than negative cases: a 5-year follow-up study. 81
The Mutation Profile Of Medullary Thyroid Carcinoma Can Be Different In Primary And Metastatic Tissues 81
Clinical Impact Of Ret Genetic Screening Of In The Management Of Medullary Thyroid Carcinoma (MTC) Patients: 20 Years Of Experience 81
No difference in the outcome of metastatic thyroid cancer patients when using recombinant or endogenous TSH 79
Significato prognostico della mutazione di BRAF in pazienti affetti da carcinoma papillare della tiroide con follow-up di 20 anni. 78
Influence of Lymphocytic Thyroiditis at Histology and Serum Thyroglobulin Autoantibodies on the Course of Papillary Thyroid Carcinoma 77
null 70
Predictive Value Of High Sensitive Thyroglobulin Assay (USTG) And Neck Ultrasonography (US) At The Time Of Remnant Ablation On Lt-4 Therapy In Patients With Low And Intermediate Risk Differentiated Thyroid Cancer (DTC) 70
MON-490 Calcitonin-Based Thyroidectomy Is a Safe Approach in Patients with Germline RET Mutation and Permits to Delay Surgery in Children 66
Ca19.9 positivity and doubling time are prognostic factors of mortality in patients with advanced medullary thyroid cancer with no evidence of structural disease progression according to RECIST 62
Fenotipo misto MEN2A/MEN2B da nuova mutazione germinale di RET: prima descrizione clinico-genetica e iconografia 62
Delayed radioiodine remnant ablation (RRA) does not impact on the outcome of intermediate risk for recurrence differentiated thyroid cancer patients (IR-DTC). 62
Impact of the Stimulation method Used for 131-Therapy in Patients With Differentiated Thyroid Cancer. 57
null 54
Thyroid cancers: From surgery to current and future systemic therapies through their molecular identities 54
Non thyroidal second primary malignancies in differentiated thyroid cancer patients: is the incidence increased comparing to the general population and could it be a radioiodine therapy consequence? 53
OR21-01 Pre-Operative Calcitonin Value as a Predictive Factor of Cancer Related Death in Sporadic Medullary Thyroid Carcinoma 51
The outcome of metastatic differentiated thyroid cancer is similar in patients prepared for 131-I therapy with recombinant TSH or Hypothyroidism. 50
Follicular (FVPTC) VS Classical (CVPTC) variant of papillary thyroid cancer: correlation of the outcome after 12 years of follow up. 50
Re: "Symptomatic Biliary Disorders During Lenvatinib Treatment for Thyroid Cancer: An Underestimated Problem" by Nervo et al 50
Assessing mPTC Progression during Active Surveillance: Volume or Diameter Increase? 50
Totale 11.024
Categoria #
all - tutte 30.283
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 30.283


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019150 0 0 0 0 0 0 0 0 0 0 0 150
2019/20202.356 250 124 202 112 224 254 249 113 151 270 374 33
2020/2021912 154 39 143 28 49 84 47 54 57 82 45 130
2021/20221.310 34 46 22 101 284 169 37 56 67 69 89 336
2022/20232.398 280 390 203 186 209 246 44 171 476 21 157 15
2023/20241.588 161 174 220 110 214 283 114 52 28 22 77 133
Totale 11.832